The EPIVER Randomized Controlled Trial

NACompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

December 30, 2020

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2024

Conditions
ST Elevation Myocardial InfarctionPercutaneous Coronary InterventionNo-Reflow Phenomenon
Interventions
DRUG

Standard therapy

Standard therapy as follows: adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.

DRUG

Epinephrine

Standard therapy plus epinephrine as follows: epinephrine, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.

DRUG

Verapamil

Standard therapy plus verapamil as follows: verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.

DRUG

Epinephrine + verapamil

Standard therapy plus epinephrine + verapamil as follows: epinephrine, verapamil, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.

Trial Locations (1)

Unknown

Cardiology Research Institute, Tomsk NRMC, Tomsk

All Listed Sponsors
lead

Tomsk National Research Medical Center of the Russian Academy of Sciences

OTHER

NCT04573751 - The EPIVER Randomized Controlled Trial | Biotech Hunter | Biotech Hunter